Zoetis Inc. (NYSE:ZTS) is ranked among the 14 Best Pharma Dividend Stocks to Buy in 2026. BofA downgraded Zoetis to Neutral from Buy, with a price target cut to $135 from $165 on December 15. Health Canada approved Zoetis’ Portela for osteoarthritis pain relief in cats with a single injection that lasts up to three months.

Portela, targeting anti-nerve growth factor, effectively reduces OA pain in cats, including those with kidney disease. Zoetis expects to make Portela available in Canada and the EU in 2026. Zoetis aims to improve animal health with innovative products like Portela and Solensia. Zoetis is the largest global animal health company focused on advancing care for animals worldwide.

Rob Polzer, Ph.D., of Zoetis, highlights Health Canada’s approval of Portela, offering a new way to manage osteoarthritis pain in cats. Zoetis expands its animal health portfolio with innovative treatments like Portela and Solensia for OA pain relief in cats. Zoetis seeks to improve animal health and quality of life through new therapies.

Read more at Yahoo Finance: BofA Downgrades Zoetis (ZTS) to Neutral, Cuts Price Target